Silence Therapeutics plc Board of Directors

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Mr. Craig A. Tooman M.B.A.

Mr. Craig A. Tooman M.B.A.

President, CEO & Executive Director

Dr. Steven J. Romano M.D.

Dr. Steven J. Romano M.D.

Executive VP and Chief Research & Development Officer

Ms. Gianine Esposito

Ms. Gianine Esposito

Chief Human Resources Officer

Ms. Rhonda L. Hellums

Ms. Rhonda L. Hellums

Executive VP, CFO & Secretary

Ms. Gem Gokmen Hopkins

Ms. Gem Gokmen Hopkins

Head of IR & Corporate Communications

Dr. Eric Floyd M.B.A., M.S., Ph.D.

Dr. Eric Floyd M.B.A., M.S., Ph.D.

Senior Vice President of Regulatory Affairs & Quality Assurance

Mr. J.P. Gabriel

Mr. J.P. Gabriel

Chief Technical Operations Officer

Dr. Barbara A. Ruskin J.D., Ph.D.

Dr. Barbara A. Ruskin J.D., Ph.D.

Senior VP and Chief Intellectual Property & Innovation Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.